Irish Medicines Board proposes revised fee structure for 2010
This article was originally published in SRA
The Irish Medicines Board has proposed a revised fee structure for the financial year 2010 that takes into account the new European Union regulation on variations (Regulation EC 1234/2008), which comes into force on 1 January1,2.
You may also be interested in...
The Netherlands-based GetReal Institute builds on seven years of multi-stakeholder collaboration to promote greater understanding of real-world evidence.
With the COVID-19 pandemic exacerbating the challenges of recruiting patients for studies targeting catastrophic diseases and rare cancers, regulators are becoming more receptive to new ways of using real-world evidence in clinical trials.
Companies can get the European Medicines Agency’s scientific opinion for their products’ use in EU and non-EU countries at about the same time.